<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02007122</url>
  </required_header>
  <id_info>
    <org_study_id>CEFTAROLINE_RRT</org_study_id>
    <nct_id>NCT02007122</nct_id>
  </id_info>
  <brief_title>Multiple-dose Pharmacokinetics of Ceftaroline During Continuous and Intermittent Renal Replacement Therapy in Patients Requiring Renal Replacement Therapy</brief_title>
  <official_title>Multiple-dose Pharmacokinetics of Ceftaroline During Continuous and Intermittent Renal Replacement Therapy in Patients Requiring Renal Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted to investigate the pharmacokinetics of ceftaroline during
      continuous and intermittent renal replacement therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Influence of renal replacement therapy on the area under concentration curve of ceftaroline plasma concentration levels.</measure>
    <time_frame>day 15</time_frame>
    <description>Pharmacokinetic samples are drawn on multiple timepoints from each patient during his participation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Infection During Renal Replacement Therapy</condition>
  <arm_group>
    <arm_group_label>IRRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftaroline levels are measured in patients receiving intermittent renal replacement therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftaroline levels are measured in patients receiving continuous renal replacement therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ceftaroline in CRRT</intervention_name>
    <description>Plasma levels of ceftaroline will be measured in patients receiving CRRT</description>
    <arm_group_label>CRRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ceftaroline in IRRT</intervention_name>
    <description>Ceftaroline plasma levels will be measured in patients receiving intermittent renal replacement therapy</description>
    <arm_group_label>IRRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years, able to give written informed consent

          -  Suspected or proven bacterial infection requiring parenteral antibiotic therapy.

          -  Renal replacement therapy (continuous or intermittent)

        Exclusion Criteria:

          -  Known hypersensitivity to ceftaroline or other cephalosporins, or severe
             hypersensitivity (anaphylactic reaction) to beta-lactam antibacterial agents.

          -  An expected survival of less than two days.

          -  Known pregnancy

          -  Coadministration of valproic acid or probenecid, which cannot be discontinued for the
             duration of the study

          -  Ceftaroline as monotherapy for resistent species or fungal infections.

          -  Other reasons oposing the study participation on the discretion of the investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Florian Thalhammer, Prof. MD</last_name>
    <phone>0043 1 40400</phone>
    <phone_ext>4440</phone_ext>
    <email>florian.thalhammer@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1190</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Thalhammer, Prof. MD</last_name>
      <phone>0043140400</phone>
      <email>florian.thalhammer@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Florian Thalhammer, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias G Vossen, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2013</study_first_submitted>
  <study_first_submitted_qc>December 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2013</study_first_posted>
  <last_update_submitted>May 29, 2017</last_update_submitted>
  <last_update_submitted_qc>May 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Florian Thalhammer</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>HD</keyword>
  <keyword>CVVH</keyword>
  <keyword>renal replacement therapy</keyword>
  <keyword>ceftaroline</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

